Research programme: N-type calcium channel antagonists - Neuromed/Merck
Latest Information Update: 16 Jun 2009
At a glance
- Originator Neuromed Pharmaceuticals
- Developer Merck & Co; Neuromed Pharmaceuticals
- Class Small molecules
- Mechanism of Action N-type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 16 Jun 2009 Discontinued - Preclinical for Pain in Canada (PO)
- 25 Mar 2008 Preclinical development is ongoing
- 08 Aug 2007 Preclinical development is ongoing